Cargando…

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer

The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase th...

Descripción completa

Detalles Bibliográficos
Autores principales: Soriano, Jorge L., Batista, Noyde, Santiesteban, Eduardo, Lima, Mayté, González, Joaquín, García, Robin, Zarza, Yohanka, López, María V., Rodríguez, Myriam, Loys, Jorge L., Montejo, Narciso, Aguirre, Frank, Macías, Amparo, Vázquez, Ana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262579/
https://www.ncbi.nlm.nih.gov/pubmed/22295231
http://dx.doi.org/10.4061/2011/710292
_version_ 1782221746389123072
author Soriano, Jorge L.
Batista, Noyde
Santiesteban, Eduardo
Lima, Mayté
González, Joaquín
García, Robin
Zarza, Yohanka
López, María V.
Rodríguez, Myriam
Loys, Jorge L.
Montejo, Narciso
Aguirre, Frank
Macías, Amparo
Vázquez, Ana M.
author_facet Soriano, Jorge L.
Batista, Noyde
Santiesteban, Eduardo
Lima, Mayté
González, Joaquín
García, Robin
Zarza, Yohanka
López, María V.
Rodríguez, Myriam
Loys, Jorge L.
Montejo, Narciso
Aguirre, Frank
Macías, Amparo
Vázquez, Ana M.
author_sort Soriano, Jorge L.
collection PubMed
description The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally daily and 2.5 mg of methotrexate orally bi-daily), in combination with five bi-weekly subcutaneous injections of 1 mg of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was 18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild. Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration.
format Online
Article
Text
id pubmed-3262579
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-32625792012-01-31 Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer Soriano, Jorge L. Batista, Noyde Santiesteban, Eduardo Lima, Mayté González, Joaquín García, Robin Zarza, Yohanka López, María V. Rodríguez, Myriam Loys, Jorge L. Montejo, Narciso Aguirre, Frank Macías, Amparo Vázquez, Ana M. Int J Breast Cancer Clinical Study The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally daily and 2.5 mg of methotrexate orally bi-daily), in combination with five bi-weekly subcutaneous injections of 1 mg of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was 18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild. Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration. SAGE-Hindawi Access to Research 2011 2011-07-14 /pmc/articles/PMC3262579/ /pubmed/22295231 http://dx.doi.org/10.4061/2011/710292 Text en Copyright © 2011 Jorge L. Soriano et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Soriano, Jorge L.
Batista, Noyde
Santiesteban, Eduardo
Lima, Mayté
González, Joaquín
García, Robin
Zarza, Yohanka
López, María V.
Rodríguez, Myriam
Loys, Jorge L.
Montejo, Narciso
Aguirre, Frank
Macías, Amparo
Vázquez, Ana M.
Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
title Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
title_full Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
title_fullStr Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
title_full_unstemmed Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
title_short Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
title_sort metronomic cyclophosphamide and methotrexate chemotherapy combined with 1e10 anti-idiotype vaccine in metastatic breast cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262579/
https://www.ncbi.nlm.nih.gov/pubmed/22295231
http://dx.doi.org/10.4061/2011/710292
work_keys_str_mv AT sorianojorgel metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT batistanoyde metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT santiestebaneduardo metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT limamayte metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT gonzalezjoaquin metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT garciarobin metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT zarzayohanka metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT lopezmariav metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT rodriguezmyriam metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT loysjorgel metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT montejonarciso metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT aguirrefrank metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT maciasamparo metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer
AT vazquezanam metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer